AKBA Stock Price
$1.12 (+1.04%)
At 2024-05-30 20:00:00 ESTAkebia Therapeutics, Inc
(NASDAQ:AKBA) 
Akebia Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of renal therapeutics for patients with kidney diseases. The company's lead product investigational product candidate is vadadustat, an oral therapy, which is in Phase III development for the tre...
Website: http://www.akebia.com
Full Time Employees: 358
Sector: Healthcare
Industry: Biotechnology
Next Earnings Date: 2023-08-03
AKBA - Daily
Date: 2024-05-31, O: 1.07, H: 1.15, L: 1.07, C: 1.12, Volume: 2,113,049
10EMA: 1.1120EMA: 1.1850EMA: 1.32100EMA: 1.37200EMA: 1.32
10EMA: 1.1120EMA: 1.1850EMA: 1.32100EMA: 1.37200EMA: 1.32
NASDAQ:AKBA Stock Key Statistics
| Basic Info: | |||
| Market Cap: | 226.70M | Exchange: | NASDAQ |
| Shares Outstanding: | 209,372,000 | Number of Employees: | 358 |
| Advanced Info: | |||
| Beta: | 0.84 | Return on Equity (ROE) ttm: | 150.00% |
| Return on Assets (ROA) ttm: | -17.00% | Earnings per Share (EPS) ttm: | -0.28 |
| Book value per Share: | -0.16 | Cash per Share: | 0.21 |
| Current ast per Share: | 0.58 | ||
| Key Ratios: | |||
| P/E ttm: | -5.43 | P/E forward: | |
| P/E ttm high: | -2.9 | P/E ttm low: | -12.19 |
| P/S ttm: | 1.16 | P/B ttm: | 3.06 |
| P/FCF ttm: | -9.69 | PEG ratio: | |
| Cash Ratios: | |||
| Cash Ratio ttm: | 0.43 | Quick Ratio ttm: | 0.82 |
| Current Ratio ttm: | 1.18 | ||
| Margins: | |||
| Gross Margin ttm: | 62.09% | EBITDA Margin ttm: | -3.53% |
| Operating Margin ttm: | 5.26% | Net Income Margin ttm: | -21.46% |
| Dividends: | |||
| Trailing Dividend yield: | Forward Dividend yield: | ||
| Payout Ratio ttm: | Ex-Dividend date: | None | |
| Target Prices: | |||
| Target Price High: | 2 USD | Target Price Low: | 2 USD |
| Target Price Mean: | 2 USD | Number of Analysts: | 2 |
| Debt: | |||
| Debt Ratio ttm: | 0.39 | Debt to Equity ttm: | -3.11 |
| Total Net Debt: | 52.31M | ||
The information provided in this report is taken from www.sec.gov. While we have conducted our best efforts to ensure that the parsed data is accurate, we cannot guarantee its accuracy. Please use caution and understand that any consequences of its use are your own responsibility.